Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Novartis
Covington
Cantor Fitzgerald
Farmers Insurance
Accenture
McKinsey
Merck
Queensland Health
Dow

Generated: August 17, 2017

DrugPatentWatch Database Preview

RIVASTIGMINE Drug Profile

« Back to Dashboard

What is the patent landscape for Rivastigmine, and what generic Rivastigmine alternatives are available?

Rivastigmine is a drug marketed by Alvogen Malta, Watson Labs, Dr Reddys Labs Inc, Sun Pharm Inds Ltd, Cadila Pharms Ltd, Macleods Pharms Ltd, Apotex Inc, Aurobindo Pharma Ltd, Orchid Hlthcare, and Alembic Pharms Ltd. and is included in ten NDAs.

The generic ingredient in RIVASTIGMINE is rivastigmine tartrate. There are thirty-two drug master file entries for this compound. Seventeen suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the rivastigmine tartrate profile page.

Summary for Tradename: RIVASTIGMINE

Patents:0
Applicants:10
NDAs:10
Suppliers / Packagers: see list1
Bulk Api Vendors: see list45
Clinical Trials: see list77
Patent Applications: see list4,007
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:RIVASTIGMINE at DailyMed

Pharmacology for Tradename: RIVASTIGMINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Orchid Hlthcare
RIVASTIGMINE TARTRATE
rivastigmine tartrate
CAPSULE;ORAL090879-001Jun 10, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Aurobindo Pharma Ltd
RIVASTIGMINE TARTRATE
rivastigmine tartrate
CAPSULE;ORAL204572-001Mar 25, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Orchid Hlthcare
RIVASTIGMINE TARTRATE
rivastigmine tartrate
CAPSULE;ORAL090879-002Jun 10, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Aurobindo Pharma Ltd
RIVASTIGMINE TARTRATE
rivastigmine tartrate
CAPSULE;ORAL204572-002Mar 25, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Alvogen Malta
RIVASTIGMINE
rivastigmine
FILM, EXTENDED RELEASE;TRANSDERMAL204403-001Sep 3, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Dow
Chubb
Chinese Patent Office
Covington
Cerilliant
Teva
Fish and Richardson
Fuji
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot